News
- Author:
- Sharon Worcester, MA
Publish date: December 20, 2023
Retrospective study shows that the proposed new systems offer more refined risk classifications in stages of myeloma.
News
- Author:
- Sharon Worcester, MA
Publish date: December 14, 2023
Fresh data confirm that a second transplant does not improve survival vs. standard two-drug regimen for relapsed myeloma.
News
- Author:
- Sharon Worcester, MA
Publish date: December 13, 2023
Certain patients with NPM1-mutated acute myeloid leukemia and measurable residual disease were shown to benefit from transplantation.
News
- Author:
- Sharon Worcester, MA
Publish date: December 11, 2023
New research suggests that CAR T-cell therapy might prove to be a game-changing treatment for lupus and two other autoimmune diseases.
News
- Author:
- Sharon Worcester, MA
Publish date: December 6, 2023
The first oral monotherapy for a rare chronic blood disorder, paroxysmal nocturnal hemoglobinuria, has been approved by the FDA.
News
- Author:
- Sharon Worcester, MA
Publish date: December 4, 2023
Management of premenopausal women with early breast cancer undergoing chemotherapy should include adapted strategies for risk communication, person...
News
- Author:
- Sharon Worcester, MA
Publish date: November 29, 2023
The agency is evaluating the need for regulatory action on the links between CAR T-cell immunotherapies and secondary blood cancers.
News
- Author:
- Sharon Worcester, MA
Publish date: November 17, 2023
The FDA also approved a companion diagnostic device, the FoundationOne CDx assay, to identify patients who are eligible for treatment with capivase...
News
- Author:
- Sharon Worcester, MA
Publish date: November 13, 2023
First drug to treat TTP. a rare, lethal blood clotting disorder, has been greenlighted by the FDA.
News
- Author:
- Sharon Worcester, MA
Publish date: November 8, 2023
Policy interventions and advocacy efforts at the patient, clinician, and hospital level will be needed to reform the PA process.
News
- Author:
- Sharon Worcester, MA
Publish date: November 8, 2023
Extended follow-up of DESTINY-Breast04 confirms survival benefit of T-DXd for HER2-low advanced breast cancer.
News
- Author:
- Sharon Worcester, MA
Publish date: October 22, 2023
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs. chemotherapy in resected stage IB-IIIA NSCLC.
News
- Author:
- Sharon Worcester, MA
Publish date: October 22, 2023
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus ...
News
- Author:
- Sharon Worcester, MA
Publish date: October 19, 2023
Approval was based on findings from a phase 3 trial, which randomly assigned 790 patients to receive nivolumab or placebo by intravenous infus...
News
- Author:
- Sharon Worcester, MA
Publish date: October 12, 2023
The test can identify genetic variants that increase an individual’s risk of certain cancers and help identify potential cancer-related hereditary ...
